LCGC International spoke to Szabolcs Fekete of Waters Corporation, corresponding author of a recent paper which introduces ...
The PCS5 trial is a Canadian multicenter, open-label, phase III randomized trial that included men with histologically proven, clinically localized prostate cancer with ≥1 high-risk feature (s) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback